The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Unmet needs and upcoming therapies in CTCL
Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, discusses unmet needs in the field of cutaneous T-cell lymphoma (CTCL), highlighting challenges around diagnosis in the early-stage setting, and the need for a cure. For late-stage CTCL, Dr Assaf comments on the need for a longer time to next treatment and to achieve higher rates of complete remission, commenting on the potential benefits of exploring novel combinations of existing approved therapies. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
